348 related articles for article (PubMed ID: 9922153)
1. Evidence that C1q binds specifically to CH2-like immunoglobulin gamma motifs present in the autoantigen calreticulin and interferes with complement activation.
Kovacs H; Campbell ID; Strong P; Johnson S; Ward FJ; Reid KB; Eggleton P
Biochemistry; 1998 Dec; 37(51):17865-74. PubMed ID: 9922153
[TBL] [Abstract][Full Text] [Related]
2. The systemic lupus erythematosus (SLE) disease autoantigen-calreticulin can inhibit C1q association with immune complexes.
Kishore U; Sontheimer RD; Sastry KN; Zappi EG; Hughes GR; Khamashta MA; Reid KB; Eggleton P
Clin Exp Immunol; 1997 May; 108(2):181-90. PubMed ID: 9158084
[TBL] [Abstract][Full Text] [Related]
3. Release of calreticulin from neutrophils may alter C1q-mediated immune functions.
Kishore U; Sontheimer RD; Sastry KN; Zaner KS; Zappi EG; Hughes GR; Khamashta MA; Strong P; Reid KB; Eggleton P
Biochem J; 1997 Mar; 322 ( Pt 2)(Pt 2):543-50. PubMed ID: 9065775
[TBL] [Abstract][Full Text] [Related]
4. Fine specificity of autoantibodies to calreticulin: epitope mapping and characterization.
Eggleton P; Ward FJ; Johnson S; Khamashta MA; Hughes GR; Hajela VA; Michalak M; Corbett EF; Staines NA; Reid KB
Clin Exp Immunol; 2000 May; 120(2):384-91. PubMed ID: 10792392
[TBL] [Abstract][Full Text] [Related]
5. Localisation of the C1q binding site within C1q receptor/calreticulin.
Stuart GR; Lynch NJ; Lu J; Geick A; Moffatt BE; Sim RB; Schwaeble WJ
FEBS Lett; 1996 Nov; 397(2-3):245-9. PubMed ID: 8955356
[TBL] [Abstract][Full Text] [Related]
6. A recombinant homotrimer, composed of the alpha helical neck region of human surfactant protein D and C1q B chain globular domain, is an inhibitor of the classical complement pathway.
Kishore U; Strong P; Perdikoulis MV; Reid KB
J Immunol; 2001 Jan; 166(1):559-65. PubMed ID: 11123337
[TBL] [Abstract][Full Text] [Related]
7. C1q inhibits autoantibody binding to calreticulin.
Racila DM; Sontheimer RD
Lupus; 1999; 8(4):300-4. PubMed ID: 10413209
[TBL] [Abstract][Full Text] [Related]
8. Lysine 322 in the human IgG3 C(H)2 domain is crucial for antibody dependent complement activation.
Thommesen JE; Michaelsen TE; Løset GÅ; Sandlie I; Brekke OH
Mol Immunol; 2000 Nov; 37(16):995-1004. PubMed ID: 11395138
[TBL] [Abstract][Full Text] [Related]
9. Anti-C1q receptor/calreticulin autoantibodies in patients with systemic lupus erythematosus (SLE).
van den Berg RH; Siegert CE; Faber-Krol MC; Huizinga TW; van Es LA; Daha MR
Clin Exp Immunol; 1998 Feb; 111(2):359-64. PubMed ID: 9486404
[TBL] [Abstract][Full Text] [Related]
10. The C1q and collectin binding site within C1q receptor (cell surface calreticulin).
Stuart GR; Lynch NJ; Day AJ; Schwaeble WJ; Sim RB
Immunopharmacology; 1997 Dec; 38(1-2):73-80. PubMed ID: 9476117
[TBL] [Abstract][Full Text] [Related]
11. Modular organization of the carboxyl-terminal, globular head region of human C1q A, B, and C chains.
Kishore U; Gupta SK; Perdikoulis MV; Kojouharova MS; Urban BC; Reid KB
J Immunol; 2003 Jul; 171(2):812-20. PubMed ID: 12847249
[TBL] [Abstract][Full Text] [Related]
12. Functional characterization of a recombinant form of the C-terminal, globular head region of the B-chain of human serum complement protein, C1q.
Kishore U; Leigh LE; Eggleton P; Strong P; Perdikoulis MV; Willis AC; Reid KB
Biochem J; 1998 Jul; 333 ( Pt 1)(Pt 1):27-32. PubMed ID: 9639558
[TBL] [Abstract][Full Text] [Related]
13. Crystal structure of
Jia Z; Yu W; Li J; Zhang M; Zhan B; Yan L; Ming Z; Cheng Y; Tian X; Shao S; Huang J; Zhu X
Front Immunol; 2024; 15():1404752. PubMed ID: 38690267
[TBL] [Abstract][Full Text] [Related]
14. The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding.
Morgan A; Jones ND; Nesbitt AM; Chaplin L; Bodmer MW; Emtage JS
Immunology; 1995 Oct; 86(2):319-24. PubMed ID: 7490135
[TBL] [Abstract][Full Text] [Related]
15. Calreticulin is released from activated neutrophils and binds to C1q and mannan-binding protein.
Eggleton P; Lieu TS; Zappi EG; Sastry K; Coburn J; Zaner KS; Sontheimer RD; Capra JD; Ghebrehiwet B; Tauber AI
Clin Immunol Immunopathol; 1994 Sep; 72(3):405-9. PubMed ID: 8062452
[TBL] [Abstract][Full Text] [Related]
16. Specific inhibition of the classical complement pathway by C1q-binding peptides.
Roos A; Nauta AJ; Broers D; Faber-Krol MC; Trouw LA; Drijfhout JW; Daha MR
J Immunol; 2001 Dec; 167(12):7052-9. PubMed ID: 11739526
[TBL] [Abstract][Full Text] [Related]
17. In silico and in vitro studies on the protein-protein interactions between Brugia malayi immunomodulatory protein calreticulin and human C1q.
Yadav S; Gupta S; Selvaraj C; Doharey PK; Verma A; Singh SK; Saxena JK
PLoS One; 2014; 9(9):e106413. PubMed ID: 25184227
[TBL] [Abstract][Full Text] [Related]
18. Amblyomma americanum tick calreticulin binds C1q but does not inhibit activation of the classical complement cascade.
Kim TK; Ibelli AM; Mulenga A
Ticks Tick Borne Dis; 2015 Feb; 6(1):91-101. PubMed ID: 25454607
[TBL] [Abstract][Full Text] [Related]
19. Pathophysiological roles of calreticulin in autoimmune disease.
Eggleton P; Llewellyn DH
Scand J Immunol; 1999 May; 49(5):466-73. PubMed ID: 10320638
[TBL] [Abstract][Full Text] [Related]
20. Domain-switched mouse IgM/IgG2b hybrids indicate individual roles for C mu 2, C mu 3, and C mu 4 domains in the regulation of the interaction of IgM with complement C1q.
Chen FH; Arya SK; Rinfret A; Isenman DE; Shulman MJ; Painter RH
J Immunol; 1997 Oct; 159(7):3354-63. PubMed ID: 9317134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
